Coming soon:, , , , . , etc

Pharma News
Source: Thailand Medical News  Nov 17, 2019
A panel of specialists from the US Food and Drug Administration has approved allowing Amarin Corp Plc's fish-oil derived drug, Vascepa to be used as an add-on therapy for reducing the chance of heart attack and stroke in high-risk patients with cardiovascular disease.   Everyone of the 16 panelists voted that the drug should be sold as a medicine to reduce the risk of cardiovascular eve...
Source: Thailand Medical News  Nov 07, 2019
Pharma giant, Biogen has signed a commercialisation agreement with Samsung Bioepis for biosimilar candidates SB11 (ranibizumab) and SB15 (aflibercept).   SB11, referencing Lucentis, is in Phase III clinical trial and SB15, referencing Eylea, is a pre-clinical candidate. The deal will allow Biogen to commercialise the biosimilars in the US, Canada, Europe, Japan and Australia. Lucentis ...